A 2-week diagnostic continuous glucose monitor, fasting insulin, HOMA-IR, and ApoB give us a real baseline then we track how your glucose, insulin, and lipid profile actually respond to the medication, not just the scale
On August 28, 2024, Eli Lilly and Company submitted a nomination to request that its GLP-1 product, tirzepatide, be added to FDAs Demonstrable Difficulties for Compounding (DDC) lists
Bicarnesine 2
We think liraglutide is protecting the brain possibly by reducing inflammation, lowering insulin resistance and the toxic effects of Alzheimers biomarkers or improving how the brains nerve cells communicate, said study researcher Paul Edison, a professor of neuroscience at Imperials Department of Brain Sciences, in a statement from the university